DynaGen Inc. announced Monday that it has started selling itsdiagnostic test for determining whether tuberculosis (TB)patients comply with their drug therapy regimen.

The diagnostic strip urine test, Mycodyn Uritec, detectsisonicotinic acid, a metabolic byproduct of isoniazid, the drug ofchoice for treating TB.

Tuberculosis is once again becoming a health threat in the U.S.,largely because it is an opportunistic infection that flourishes inimmunocompromised people, such as those who have AIDS.Worldwide, 20 million people have the disease, and 3 milliondie from it every year, according to the World HealthOrganization.

"Compliance with antibiotic treatments is critical for controllingTB," said Indu Muni, DynaGen's president and chief executiveofficer. "Although treatable if detected early enough, TB canrelapse if the patient does not consistently comply with anti-TBtherapy, which often lasts for six to nine months," Muniexplained.

Stock in DynaGen (NASDAQ:DYGN) of Cambridge, Mass., wasdown 25 cents a share on Monday to $5.13.

(c) 1997 American Health Consultants. All rights reserved.

No Comments